Study links psychedelic use to lower migraine rates in Swedish twins
A large twin study found people who use psychedelics report significantly fewer migraines, though the effect appeared stronger in men than women. The finding adds real-world evidence to early clinical trials and could reshape how pharmaceutical and biotech companies approach migraine treatment development.
Originaltitel: Associations between psychedelic use and migraine history in Swedish twins
BACKGROUND: While psychedelics have shown initial promise in the treatment of migraine, experimental studies have relied on small and homogenous samples, which limit the reliability and generalizability of findings. These limitations underscore the complementary value of other research designs that leverage larger and more representative samples. METHODS: This cross-sectional study included three cohorts of twins from the Swedish Twin Registry and evaluated associations between psychedelic use and migraine history. RESULTS: = 0.008). Notably, subgroup analyses showed that these results were broadly the same when only males were included in the models, but no significant associations were observed in female-only models. CONCLUSIONS: The findings from this twin study suggest that psychedelics may be linked to a lower likelihood of migraine, with potential differences by sex. This warrants further investigation and highlights the importance of sex-specific analyses in future studies.